Cargando…
Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan
Both overall survival (OS) and progression‐free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, the impact of oncology drug prices on OS and PFS is unclear. We analyzed the...
Autores principales: | Satoh, Etsuko, Sasaki, Yasutsuna, Ohkuma, Ryotaro, Takahashi, Takehiro, Kubota, Yutaro, Ishida, Hiroo, Hamada, Kazuyuki, Kiuchi, Yuji, Tsunoda, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272097/ https://www.ncbi.nlm.nih.gov/pubmed/30315613 http://dx.doi.org/10.1111/cas.13831 |
Ejemplares similares
-
Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Sasaki, Yasutsuna, et al.
Publicado: (2015) -
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
por: Nio, Yuta, et al.
Publicado: (2022) -
Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan
por: Takata, Kosuke, et al.
Publicado: (2016) -
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022) -
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
por: Ohkuma, Ryotaro, et al.
Publicado: (2021)